Aging gracefully? Older blood just as effective in transfusions

How long a hospital has been storing blood doesn’t appear to have an effect on mortality, alleviating concerns about whether fresh blood was better for patients who need a transfusion.

The study was published in the New England Journal of Medicine and led by Nancy Heddle, MSc, of McMaster University in Hamilton, Ontario, Canada.

Blood can be stored up to 42 days before transfusion. Earlier studies, as detailed in a related editorial written by Aaron A.R. Tobian, MD, PhD, of John Hopkins University, found no evidence fresher blood was superior to older blood. Concerns remained about red-cell “storage lesion,” however, and suggestions that blood in certain long-term storage conditions may worsen bacterial infections.

For Heddle’s study, the data for more than 20,800 patients with either type A or type O blood who underwent transfusions at four hospitals in three countries was evaluated. Patients were split between a short-term storage group, who received blood which had been stored for 13 days, and a long-term group, receiving transfusion of 23-day-old blood.

The mortality rate was about 9 percent for both groups. When results were expanded by another 4,000 patients to include more blood types, the mortality rate remained the same.

“We did not find a significant difference in the rate of death according to the duration of blood storage among patients in a general hospital population who underwent transfusion,” Heddle and her coauthors wrote.

The findings are consistent with earlier trials referenced by Tobian. What may come next, according to Heddle, is testing transfusions using stored blood near the end of its usable life.

“None of the studies involving humans have been designed to determine whether the transfusion of the very oldest red cells (that is, those stored for 35 to 42 days) affect patient outcomes, a question that remains unresolved,” Heddle and her coauthors wrote. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.